Study of Pembrolizumab (MK-3475) in Participants With Advanced Urothelial Cancer (MK-3475-052/KEYNOTE-052)

Clinical trial NCT02335424 · COMPLETED

Trial details

NCT number: NCT02335424
Sponsor: Merck Sharp & Dohme LLC
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Urothelial Cancer

Start date: 2015-02-24
Primary completion: 2018-06-19
Enrollment: 374

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.